TTS 2024 - Join us in Istanbul!

Standard Registration extended to August 22

We will update our prices on August 23rd, take advantage and register before the rates go up!

Congress Website

Have you planned your week in Istanbul?

Start planning your TTS 2024 experience with our easy-to-use web app! Explore the program, favorite sessions, and create your personalized schedule ahead of time. Stay on top of session updates and make sure you don’t miss the presentations most relevant to you. Dive into TTS 2024 fully prepared by mapping out your must-attend sessions now!

View WebApp

View Detailed Program

View Speakers

Upcoming Webinar Presentations

Click here for details and to register

In Case You Missed It…Recent Recordings

CLICK HERE TO VIEW RECORDING

Click here to view recording

Transplantation Journal Highlights

Transplantation Direct Featured Article

Organ allocation in the United States to non-US citizen, non-US residents who travel for transplant is discussed in this paper by Ann Nguyen et al.

Organ allocation in the United States to non-US citizen, non-US residents who travel for transplant (NC/NRTx) is controversial. Current policies may not be informed by stakeholder opinions, as limited data exist assessing the knowledge or opinions of providers or patients on this issue.

Transplantation - Social Media Content

Fantastic read on various measures to improve the outcomes post transplantation with an emphasis on metabolic and cardiac risk factors.

Minimizing Metabolic and Cardiac Risk Factors to Maximize Outcomes After Liver Transplantation

Cardiovascular disease (CVD) is a leading complication after liver transplantation and has a significant impact on patients’ outcomes posttransplant. The major risk factors for post–liver transplant CVD are age, preexisting CVD, nonalcoholic fatty liver disease, chronic kidney disease, and metabolic syndrome. This review explores the contemporary strategies and approaches to minimizing cardiometabolic disease burden in liver transplant recipients. We highlight areas for potential intervention to reduce the mortality of patients with metabolic syndrome and CVD after liver transplantation.

Just another molecule? Bleselumab reduced proteinuria in comparison to Standard of Care, without any difference in incidence of biopsy-proven rFSGS.

Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study

Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage kidney disease and frequently recurs after kidney transplantation. Recurrent FSGS (rFSGS) is associated with poor allograft and patient outcomes. Bleselumab, a fully human immunoglobulin G4 anti-CD40 antagonistic monoclonal antibody, disrupts CD40−related processes in FSGS, potentially preventing rFSGS.

Transplantation Direct - Social Media Content

This study shows that CMV prophylaxis, although considered as a more expensive strategy, is more cost-effective than preemptive therapy for the prevention of CMV infections in renal transplant patients.

The Cost-effectiveness of Valganciclovir Prophylaxis Versus Preemptive Therapy in CMV R+ Kidney Transplant Recipients Over the First Year Posttransplantation

In kidney transplant recipients with positive serology (R+) for the cytomegalovirus (CMV), 2 strategies are used to prevent infection, whose respective advantages over the other are still debated. This study aimed to evaluate the cost-effectiveness and cost utility of antiviral prophylaxis against CMV versus preemptive therapy, considering CMV infection–free survival over the first year posttransplantation as the main clinical outcome.

Patients aged 70 y and older had significantly lower survival with 82.9% at 1 y and 66.5% at 3 y compared with patients in 18-49 group and kidney graft survival was 80.9% at 1 y and 66.4% at 3 y

Simultaneous Liver and Kidney Transplantation in Patients Aged 70 y and Older: Proceed With Caution

The number of elderly patients aged 70 y and older with liver and kidney failure is increasing, mainly because of increasing prevalence of metabolic dysfunction-associated steatohepatitis. At present, limited data are available on the outcomes of elderly patients who fit the criteria for dual organ transplantation since the implementation of the simultaneous liver and kidney (SLK) allocation policy.